mAbxience and OncoPrecision announced a development, manufacturing and investment agreement for ONC001, OncoPrecision’s lead antibody-drug conjugate candidate. Under the agreement, mAbxience will develop the antibody component of ONC001 and manufacture material to support a planned Phase 1 clinical trial.
mAbxience’s responsibilities will include cell line development, process development and analytical development for the antibody component. Its work will extend through the production of the first batch for clinical use under good manufacturing practice standards as the program advances toward its first study in humans.
ONC001 targets CD64 and is designed to eliminate leukemic monocytes and tumor-associated macrophages. The program’s lead indications are monocytic acute myeloid leukemia and chronic myelomonocytic leukemia, two aggressive blood cancers with limited treatment options. OncoPrecision developed the candidate using its patient-derived drug discovery platform and first disclosed it publicly in an oral presentation at the 2025 American Society of Hematology Annual Meeting.
As part of the agreement, mAbxience has made an investment in OncoPrecision, a New York City-based biotechnology company developing therapies for hard-to-treat cancers. Jurgen Van Broeck, chief executive officer of mAbxience, will join OncoPrecision’s board of directors as an observer. mAbxience is a wholly owned subsidiary of Fresenius SE & Co. KGaA.